MANILA, Philippines, Aug. 13, 2025 /PRNewswire/ -- The Philippine government has partnered with the country's leading e-wallet in line with its agenda to modernize the local transportation sector with world-class payment solutions.
The Department of Transportation (DOTr), the country's central bank, Bangko Sentral ng Pilipinas (BSP), the Department of Information and Communications Technology (DICT), and leading local fintech giant GCash have launched world-class cashless solutions in Metro Manila's main rail line, the Metro Rail Transit System Line 3 (MRT-3).
This initiative positions the Philippines in the same category as its Southeast Asian neighbors, such as Singapore, which have implemented open-loop ticketing systems, which reduces friction for commuters, allowing them to use various cashless modes of payment.
The newly launched Automated Fare Collection System enables faster, easier journeys for MRT-3 passengers via a tap-in and tap-out method through multiple modes of payment: QR, mobile NFC, and debit/credit cards.
"This is just the beginning. We're working on this to make all turnstile carousels [equipped] with this option for various payment modes," said Transport Secretary Vince Dizon, adding the digital payment solutions will soon be available in other rail lines — the Light Rail Transit Lines 1 and 2, and other mass transport systems.
"One of our core mandates is to make payments safer, secure, efficient, reliable, and more accessible to all. Today, those two goals come together," said Walter Wassmer, member of the central bank's Monetary Board.
To help ensure the success of this initiative, DICT Secretary Henry Aguda said they have been working to enhance internet connectivity at MRT-3, allowing commuters to access the GCash app whenever.
"We're so proud and excited to finally launch this service in partnership with the government," said Martha Sazon, President & CEO of Mynt, the holding company of GCash. "Before, people would line up as early as 4:30 am just to buy a ticket. I hope that with this project, we can help them make their commute faster and more convenient."
About GCash
GCash is the Philippines' #1 Finance Super App and Largest Cashless Ecosystem. Through the GCash App, users can easily purchase prepaid airtime; pay bills via partner billers nationwide; send and receive money anywhere in the Philippines, even to other bank accounts; purchase from over 6 million partner merchants and social sellers; and get access to savings, credit, loans, insurance and invest money, and so much more, all at the convenience of their smartphones. Its mobile wallet operations are handled by G-Xchange, Inc. (GXI), a wholly-owned subsidiary of Mynt, the first and only $5 billion unicorn in the Philippines.
GCash is a staunch supporter of the United Nations Sustainable Development Goals (SDGs), particularly UN SDGs 5,8,10, and 13, which focus on safety & security, financial inclusion, diversity, equity, and inclusion as well as taking urgent action to combat climate change and its impacts, respectively.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Ph government, top fintech firm team up to accelerate digital shift of transport sector
|
TOKYO, April 28, 2026 /PRNewswire/ -- Cordis, a global leader in interventional cardiovascular technologies, today announces the launch and availability of the SELUTION SLR™ PTA Drug-Eluting Balloon (DEB)1 for use in Japan.
SELUTION SLR™ DEB is designed to deliver sirolimus in a controlled, sustained manner to reduce restenosis and restore vessel function.
The SELUTION SFA Japan clinical trial results demonstrate durable clinical outcomes in a complex patient population, including 81.5% primary patency and 93.8% of patients remaining free from reintervention through three years.2 As the first sirolimus-eluting balloon approved in Japan for the treatment of peripheral artery disease, SELUTION SLR™ DEB provides an additional treatment option for physicians managing patients in real-world clinical practice.
Dr. Yoshimitsu Soga, Co-Principal Investigator of the SELUTION SFA Japan clinical trial and Director of Cardiology, Kokura Memorial Hospital said, "I am pleased to see SELUTION SLR™ DEB now available for use in clinical practice in Japan. The three-year results from the SELUTION SFA Japan clinical trial demonstrate sustained efficacy and safety, supporting its role as an important treatment option for patients."
Dr. Osamu Iida, Co-Principal Investigator of the SELUTION SFA Japan clinical trial and Director of the Department of Cardiology at Osaka International Medical & Science Center, Osaka Keisatsu Hospital said, "SELUTION SLR™ DEB is a valuable addition to the treatment options for peripheral vascular disease. In my early clinical experience, I've observed strong post-procedural blood flow without evidence of downstream effects below the knee. I look forward to seeing its broader adoption in real-world clinical practice."
"At Cordis, we recognize the impact peripheral artery disease can have on patients and their daily lives," said George Adams, MD, Chief Medical Officer, Cordis. "The launch of SELUTION SLR™ DEB in Japan reflects our focus on expanding innovative treatment options that physicians may consider based on individual patient needs. We look forward to continuing to work with the medical community in Japan to support patient care."
About Cordis
From the first guidewire to the first drug-eluting stent, Cordis has been at the heart of cardiovascular innovation for nearly 70 years. Today, Cordis drives transformation through internal development, Cordis-X partnerships, and strategic acquisitions—powered by a global footprint and deep operational expertise. With a focus on better clinical outcomes, customer-centered service, and impactful education, Cordis will go beyond to relentlessly pursue its mission to transform cardiovascular care.
- Brand name: SELUTION SLR PTA drug-eluting balloon catheter Medical device approval number: 30700BZI00031000
- Soga, Y. et al. 3-Year Results Following Femoropopliteal Lesion Treatment With a Novel Sirolimus-Eluting Balloon. JACC: Cardio Interv 2025. 18(21):2629-2637.
Media Contact:
Kelly May
Director, Corporate Communications
Cordis
kelly.may@cordis.com
www.cordis.com
Logo - https://mma.prnasia.com/media2/1676076/5936462/Cordis_2025_Logo.jpg?p=medium600
Photo - https://mma.prnasia.com/media2/2965333/Cordis__Launches_SELUTION_SLR_PTA_Drug_Eluting_Balloon_DEB_in_Japan.jpg?p=medium600
TOKYO, April 28, 2026 /PRNewswire/ -- Cordis, a global leader in interventional cardiovascular technologies, today announces the launch and availability of the SELUTION SLR™ PTA Drug-Eluting Balloon (DEB)1 for use in Japan.
SELUTION SLR™ DEB is designed to deliver sirolimus in a controlled, sustained manner to reduce restenosis and restore vessel function.
The SELUTION SFA Japan clinical trial results demonstrate durable clinical outcomes in a complex patient population, including 81.5% primary patency and 93.8% of patients remaining free from reintervention through three years.2 As the first sirolimus-eluting balloon approved in Japan for the treatment of peripheral artery disease, SELUTION SLR™ DEB provides an additional treatment option for physicians managing patients in real-world clinical practice.
Dr. Yoshimitsu Soga, Co-Principal Investigator of the SELUTION SFA Japan clinical trial and Director of Cardiology, Kokura Memorial Hospital said, "I am pleased to see SELUTION SLR™ DEB now available for use in clinical practice in Japan. The three-year results from the SELUTION SFA Japan clinical trial demonstrate sustained efficacy and safety, supporting its role as an important treatment option for patients."
Dr. Osamu Iida, Co-Principal Investigator of the SELUTION SFA Japan clinical trial and Director of the Department of Cardiology at Osaka International Medical & Science Center, Osaka Keisatsu Hospital said, "SELUTION SLR™ DEB is a valuable addition to the treatment options for peripheral vascular disease. In my early clinical experience, I've observed strong post-procedural blood flow without evidence of downstream effects below the knee. I look forward to seeing its broader adoption in real-world clinical practice."
"At Cordis, we recognize the impact peripheral artery disease can have on patients and their daily lives," said George Adams, MD, Chief Medical Officer, Cordis. "The launch of SELUTION SLR™ DEB in Japan reflects our focus on expanding innovative treatment options that physicians may consider based on individual patient needs. We look forward to continuing to work with the medical community in Japan to support patient care."
About Cordis
From the first guidewire to the first drug-eluting stent, Cordis has been at the heart of cardiovascular innovation for nearly 70 years. Today, Cordis drives transformation through internal development, Cordis-X partnerships, and strategic acquisitions—powered by a global footprint and deep operational expertise. With a focus on better clinical outcomes, customer-centered service, and impactful education, Cordis will go beyond to relentlessly pursue its mission to transform cardiovascular care.
- Brand name: SELUTION SLR PTA drug-eluting balloon catheter Medical device approval number: 30700BZI00031000
- Soga, Y. et al. 3-Year Results Following Femoropopliteal Lesion Treatment With a Novel Sirolimus-Eluting Balloon. JACC: Cardio Interv 2025. 18(21):2629-2637.
Media Contact:
Kelly May
Director, Corporate Communications
Cordis
kelly.may@cordis.com
www.cordis.com
Logo - https://mma.prnasia.com/media2/1676076/5936462/Cordis_2025_Logo.jpg?p=medium600
Photo - https://mma.prnasia.com/media2/2965333/Cordis__Launches_SELUTION_SLR_PTA_Drug_Eluting_Balloon_DEB_in_Japan.jpg?p=medium600
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Cordis Launches SELUTION SLR™ PTA Drug-Eluting Balloon (DEB) in Japan
